Quizartinib hydrochloride is a small molecule inhibitor primarily used in the treatment of acute myeloid leukemia (AML) with specific mutations in the FLT3 gene. It functions as a selective inhibitor of the FLT3 receptor tyrosine kinase, which is often mutated in AML, leading to uncontrolled cell proliferation. The hydrochloride salt form enhances its solubility and stability, facilitating its use in pharmaceutical formulations. Quizartinib is characterized by its ability to inhibit both the wild-type and mutated forms of FLT3, making it a targeted therapy for patients with FLT3-ITD (internal tandem duplication) mutations. The compound is typically administered orally and has undergone various clinical trials to assess its efficacy and safety profile. Its pharmacokinetics involve absorption, distribution, metabolism, and excretion, with a focus on minimizing adverse effects while maximizing therapeutic outcomes. As with many targeted therapies, monitoring for potential resistance mechanisms is crucial in clinical settings. Overall, Quizartinib hydrochloride represents a significant advancement in the treatment landscape for specific subtypes of AML.

Quizartinib hydrochloride

1132827-21-4: Quizartinib hydrochloride is a small molecule inhibitor primarily used in the treatment of acute myeloid leukemia (AML) with specific mutations in the FLT3 gene. It functions as a selective inhibitor of the FLT3 receptor tyrosine kinase, which is often mutated in AML, leading to uncontrolled cell proliferation. The hydrochloride salt form enhances its solubility and stability, facilitating its use in pharmaceutical formulations. Quizartinib is characterized by its ability to inhibit both the wild-type and mutated forms of FLT3, making it a targeted therapy for patients with FLT3-ITD (internal tandem duplication) mutations. The compound is typically administered orally and has undergone various clinical trials to assess its efficacy and safety profile. Its pharmacokinetics involve absorption, distribution, metabolism, and excretion, with a focus on minimizing adverse effects while maximizing therapeutic outcomes. As with many targeted therapies, monitoring for potential resistance mechanisms is crucial in clinical settings. Overall, Quizartinib hydrochloride represents a significant advancement in the treatment landscape for specific subtypes of AML.

<p>Quizartinib (AC220/AC010220) is an oral FLT3/STK1 inhibitor for treating AML, blocking kinase-driven cell proliferation and promoting apoptosis.</p>

Quizartinib HCl

<p>Ac 220 is a molecule that inhibits cell proliferation and induces necrotic cell death. It has been shown to inhibit the growth of solid tumours by inhibiting the production of epidermal growth factor and colony-stimulating factor. Ac 220 also inhibits the growth of cancer cells by blocking signalling pathways, such as tyrosine kinase domain. The effective dose for Ac 220 is not known yet.</p>

CAS 1132827-21-4

Quizartinib hydrochloride

Quizartinib HCl

Ref: TM-T71400

Ac 220 dihydrochloride

Ref: 3D-HVB82721